# Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma

> **NCT07235007** · NA · RECRUITING · sponsor: **Aichi Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Extrahepatic Cholangiocarcinoma

## Interventions

- **DEVICE:** Endobiliary Radiofrequency Ablation (EB-RFA)
- **DEVICE:** Plastic Biliary Stent

## Key facts

- **NCT ID:** NCT07235007
- **Lead sponsor:** Aichi Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07235007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07235007, "Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07235007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*